Overview

Academic start-ups in the OECD data produce more patents, including science-linked patents, yet are less likely to receive follow-on funding, late-stage or growth equity, and acquisition outcomes after observed characteristics are accounted for. They are not less likely to complete an IPO, so the gap is not a general verdict on company value. Possible explanations include complex technology, long development timelines, higher capital needs, founder networks, commercial capability, strategy, and selection. The evidence does not identify one universal cause. It instead separates innovation output from investor and buyer readiness and points to the need for early support that produces technical and commercial evidence usable by later capital.

Learning outcomes

More patents do not imply readiness for growth capital, manufacturing, regulation, customers, or acquisition.
In the OECD data, academic start-ups were less likely to reach late-stage or growth equity and acquisition, but not IPO.
The later gap may combine technology, networks, strategy, and selection; the evidence does not establish one cause.

Keywords

academic start-upspatentsscale-upgrowth capitalacquisitionIPO

Why the gap appears later

For academic start-ups, the later financing gap is easiest to understand by separating innovation output from the ability to attract growth capital and an exit. The OECD evidence asks whether ventures that are closely tied to science can produce more patents yet receive less follow-on funding, late-stage equity, or acquisition opportunities. That comparison helps identify what the gap may mean: not necessarily that the technology failed, but that technical novelty, investor readiness, and buyer readiness are different financial outcomes.

Innovation can advance while scale-up lags

The OECD results show a clear divergence after the first funding event. Academic start-ups file more patents than non-academic start-ups, including more patents that cite university patents and academic literature. This remains true in models that control for sector, country, founding cohort, funding year, total funding, and founder characteristics. Grants are also positively associated with patent filings and with science-linked patenting in the conditional models. The implication is that non-dilutive support can help academic ventures continue the technical work that makes their innovation visible.

But a patent is not the same as a financing milestone. It may demonstrate novelty or protect an invention, while leaving open questions about manufacturing, regulation, customer adoption, unit economics, or the cost of reaching a market. A portfolio of technically important patents can therefore coexist with a business that still needs substantial capital before it can generate reliable cash flow. The value of the innovation may be high, but the timing and probability of a financial return remain difficult to estimate.

The financing outcomes reflect that difference. After accounting for observed characteristics, academic start-ups are less likely to raise follow-on funding in the OECD data. When the analysis looks more specifically at scale, they are less likely to receive late-stage or growth equity and less likely to experience an exit through acquisition or the combined acquisition/IPO measure. They are not less likely to reach an IPO. That last result matters because it prevents the later gap from being described as a general inability to produce a valuable company. The weak point appears more specifically in continuation, scale-up, and acquisition.

A private investor’s return depends on a path from capital to a later value event. For an acquisition, a buyer must believe that the technology is worth purchasing and that it can be integrated into an existing business. For an IPO, the company must instead persuade a broader public market that its future cash flows or strategic value justify a share price, while investors collectively bear the uncertainty of commercialisation. Neither route is easy, but the risks are distributed differently. The OECD authors suggest that academic start-ups’ more complex technologies may be harder for a single buyer to assess and integrate, which would depress acquisition opportunities without necessarily lowering the probability of an IPO.

The same distinction applies to growth capital. A company can receive enough money to keep developing a technology while still lacking the amount or type of capital required for commercial scale. Academic start-ups may face higher development costs or need more financing before they reach a stage at which private investors can underwrite expansion. If the first and second rounds mainly pay for technical proof, later investors may still have to fund regulatory work, manufacturing, sales, or market education.

Published by DeepMox

FAQ

Why can acquisition be harder without IPO being less likely for academic start-ups?

Acquisition requires a buyer to assess and integrate the technology, whereas an IPO relies on broader public-market valuation; the OECD data show lower acquisition likelihood but not lower IPO likelihood.

Which later outcomes are weaker for academic start-ups in the OECD data?

The data show lower follow-on funding, late-stage or growth equity, and acquisition for academic start-ups after observed controls, but not lower IPO likelihood.

Does government venture capital close the academic start-up financing gap?

The OECD results do not show that it does: academic start-ups were not more likely to receive GovVC initially, and non-equity first funding was associated with lower follow-on GovVC; this is not proof of causal displacement.

Previous12 minAcademic Start-up Second-Round Funding

Next13 minAcademic Start-up Financing Path Design

Academic Start-up Innovation and Scale-up Gap

Why the gap appears later

Innovation can advance while scale-up lags

FAQ